See more : Aevis Victoria SA (AEVS.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Harrow Health, Inc. (HROW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harrow Health, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Jilin Chemical Fibre Stock Co.,Ltd (000420.SZ) Income Statement Analysis – Financial Results
- Euroafrica Digital Ventures AB (publ) (EURA.ST) Income Statement Analysis – Financial Results
- Centurion Acquisition Corp. (ALFUW) Income Statement Analysis – Financial Results
- Union Acquisition Corp. II (LATNW) Income Statement Analysis – Financial Results
- Direcional Engenharia S.A. (DIRR3.SA) Income Statement Analysis – Financial Results
Harrow Health, Inc. (HROW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.harrowinc.com
About Harrow Health, Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 130.19M | 88.60M | 72.48M | 48.87M | 51.17M | 41.37M | 26.77M | 19.94M | 9.72M | 1.66M | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 39.64M | 25.38M | 18.21M | 14.46M | 16.75M | 16.52M | 13.51M | 9.83M | 5.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 90.55M | 63.21M | 54.26M | 34.41M | 34.42M | 24.85M | 13.27M | 10.11M | 4.51M | 567.41K | 10.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 69.55% | 71.35% | 74.87% | 70.41% | 67.26% | 60.07% | 49.56% | 50.70% | 46.42% | 34.18% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.88M | 3.05M | 11.08M | 2.41M | 2.08M | 825.00K | 413.00K | 739.00K | 332.00K | 236.66K | 1.62M | 1.30M | 111.55K | 194.59K | 2.97M | 1.99M | 1.83M | 150.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.96M | 17.57M | 12.50M | 8.09M | 5.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 430.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.06M | 7.38M | 6.50M | 2.39M | 85.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -423.79K |
| SG&A | 83.09M | 58.24M | 41.32M | 31.25M | 33.10M | 29.24M | 25.02M | 24.95M | 19.00M | 10.48M | 6.08M | 2.98M | 827.67K | 2.31M | 1.60M | 1.76M | 2.86M | 6.21K |
| Other Expenses | 0.00 | -15.93M | -19.49M | -3.80M | 630.00K | 103.00K | 0.00 | 1.54M | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -110.00K |
| Operating Expenses | 90.12M | 61.29M | 52.40M | 33.66M | 35.18M | 30.07M | 25.43M | 25.69M | 19.33M | 10.71M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Cost & Expenses | 129.76M | 86.68M | 70.61M | 48.12M | 51.93M | 46.59M | 38.94M | 35.52M | 24.54M | 11.81M | 7.70M | 4.28M | 939.23K | 2.50M | 4.56M | 3.75M | 2.86M | 46.21K |
| Interest Income | 0.00 | 7.24M | 5.44M | 2.24M | 0.00 | 0.00 | 0.00 | 10.00K | 13.00K | 32.45K | 43.76K | 15.41K | 0.00 | 512.00 | 10.44K | 67.01K | 48.44K | 0.00 |
| Interest Expense | 21.32M | 7.24M | 5.44M | 2.24M | 2.50M | 2.73M | 3.03M | 6.00M | 1.12M | 3.80K | 0.00 | 24.66K | 75.00K | 55.48K | 0.00 | 0.00 | 1.56M | -10.00K |
| Depreciation & Amortization | 12.34M | 3.67M | 2.40M | 2.74M | 2.66M | 1.84M | 1.77M | 1.41M | 610.00K | 85.35K | 5.66K | 2.94K | 338.00 | 1.06K | 1.06K | 704.00 | 201.25K | 0.00 |
| EBITDA | 9.72M | -3.20M | -10.14M | 3.49M | 1.44M | -2.73M | -10.40M | -14.06M | -14.21M | -10.06M | -7.64M | -5.36M | -878.60K | -2.47M | -4.55M | -4.12M | -2.75M | -46.21K |
| EBITDA Ratio | 7.47% | 2.17% | 2.91% | 2.27% | 4.22% | -7.21% | -55.59% | -59.13% | -146.27% | -604.06% | -76,374.65% | -4,160.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 431.00K | -1.75M | -284.00K | -1.63M | -503.00K | -5.22M | -12.16M | -15.88M | -14.82M | -10.15M | -7.69M | -4.18M | -939.23K | -2.50M | -4.56M | -3.75M | -2.86M | -46.21K |
| Operating Income Ratio | 0.33% | -1.97% | -0.39% | -3.34% | -0.98% | -12.61% | -45.43% | -79.64% | -152.55% | -611.16% | -76,868.79% | -4,178.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -24.37M | -15.93M | -19.49M | -3.80M | 386.00K | 19.84M | -757.00K | -3.32M | -1.08M | 28.65K | 43.76K | -1.20M | -14.71K | -28.67K | 10.44K | 375.00K | -1.43M | -533.79K |
| Income Before Tax | -23.94M | -14.01M | -17.87M | -3.42M | -125.00K | 14.63M | -12.92M | -19.20M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | 0.00 | -3.37M | -2.77M | -580.00K |
| Income Before Tax Ratio | -18.39% | -15.81% | -24.66% | -6.99% | -0.24% | 35.35% | -48.26% | -96.27% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 470.00K | 75.00K | 133.00K | 4.00K | 2.47M | -19.45M | -935.00K | -111.00K | 1.08M | -28.65K | -43.76K | 1.20M | -60.29K | -26.30K | -10.44K | -817.01K | -228.27K | 10.00K |
| Net Income | -24.41M | -14.09M | -18.01M | -3.42M | -2.59M | 14.63M | -11.99M | -19.09M | -15.90M | -10.12M | -7.64M | -5.38M | -953.94K | -2.53M | -4.55M | -3.30M | -4.28M | -46.21K |
| Net Income Ratio | -18.75% | -15.90% | -24.85% | -7.00% | -5.07% | 35.35% | -44.76% | -95.71% | -163.64% | -609.43% | -76,431.24% | -5,383.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| EPS Diluted | -0.75 | -0.51 | -0.67 | -0.13 | -0.10 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.20 | -2.40 | -6.41 | -11.67 | -8.92 | -19.37 | -0.25 |
| Weighted Avg Shares Out | 32.62M | 27.46M | 26.76M | 25.90M | 25.32M | 23.81M | 19.98M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
| Weighted Avg Shares Out (Dil) | 32.62M | 27.46M | 26.76M | 25.90M | 26.47M | 23.81M | 20.03M | 12.74M | 9.58M | 9.13M | 8.66M | 4.49M | 397.80K | 394.63K | 390.32K | 370.55K | 221.17K | 185.01K |
Harrow Health, Inc. (HROW) Q2 2023 Earnings Call Transcript
Harrow Health, Inc. (NASDAQ:HROW ) Q2 2023 Earnings Conference Call August 9, 2023 4:45 PM ET Company Participants Jamie Webb - Director-Communications & Investor Relations Mark L. Baum - Chief Executive Officer & Chairman-Board of Directors Andrew Boll - Chief...
Harrow Health And Its Interesting 11.6% 2027 Baby Bond
Harrow Health is an eye care pharmaceuticals company. The common stock has been on fire with expectations of rapidly increasing profits. HROW has 2 baby bonds, with one looking particularly interesting given an 11.6% yield to maturity.
Harrow Launches VIGAMOX® in the U.S.
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for...
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, after the market close. The Company...
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Shares of Harrow Health Are Jumping Wednesday
Harrow added seven new products through an acquisition. The company said it expects increased revenue year over year in the second quarter.
Harrow Prices $60 Million Public Offering of Common Stock
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,282 shares of its common stock at a price of $17.75 per share for aggregate gross proceeds...
Harrow Acquires Santen's Branded Ophthalmic Portfolio
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co., Ltd. (“Santen”) under which Harrow will acquire certain U.S. and Canadian commercial rights for the following...
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
NASHVILLE--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the following select preliminary second quarter 2023 financial guidance: Second quarter 2023 revenues in excess of $31.0 million compared with prior-year second quarter revenues of $23.3 million...
Harrow Announces Proposed Public Offering of Common Stock
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced a proposed underwritten registered public offering of its common stock, subject to market and certain other conditions. Harrow expects to grant the underwriters a 30-day option...
Source: https://incomestatements.info
Category: Stock Reports